Teva Wins New Hearing in Glaxo ‘Skinny Label’ Drug Patent Case

A U.S. appeals court agreed to reconsider a controversial October ruling that generic-drug maker Teva Pharmaceutical Industries Ltd. said would enable brand companies to block low-cost competition.

A split three-judge panel of the U.S. Court of Appeals for the Federal Circuit had revived a $235 million patent-infringement verdict won by GlaxoSmithKline Plc over Teva’s sales of a generic version of the heart drug Coreg. The panel will rehear arguments in the case on Feb. 23 in Washington.

The dispute is over so-called “skinny labels,” used by generic-drug makers when they are selling a copycat of a branded medicine but only ...